Literature DB >> 10720556

Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria.

D Dodoo1, M Theisen, J A Kurtzhals, B D Akanmori, K A Koram, S Jepsen, F K Nkrumah, T G Theander, L Hviid.   

Abstract

The development of effective malaria vaccines depends on the identification of targets of well-defined protective immune responses. Data and samples from a longitudinal study of a cohort of children from coastal Ghana were used to investigate the role of antibody responses to 3 regions of the Plasmodium falciparum glutamate-rich protein (GLURP). The data show that levels of the GLURP-specific IgG that occurs in the nonrepeat region of the antigen are significantly correlated with clinical protection from P. falciparum malaria, after correction for the confounding effect of age. Furthermore, levels of cytophilic antibodies were found to be of particular importance for protection, lending support to the hypothesis that antibody-dependent cellular inhibition is the important element in GLURP-specific protective immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720556     DOI: 10.1086/315341

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  52 in total

1.  Baculovirus-expressed constructs induce immunoglobulin G that recognizes VAR2CSA on Plasmodium falciparum-infected erythrocytes.

Authors:  Lea Barfod; Morten A Nielsen; Louise Turner; Madeleine Dahlbäck; Anja T R Jensen; Lars Hviid; Thor G Theander; Ali Salanti
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Genetic Diversity of the Plasmodium falciparum Glutamate-Rich Protein R2 Region Before and Twelve Years after Introduction of Artemisinin Combination Therapies among Febrile Children in Nigeria.

Authors:  Christian N Nguetse; Johnson Adeyemi Ojo; Charles Nchotebah; Moses Nkechukwu Ikegbunam; Christian G Meyer; Bolaji N Thomas; Thirumalaisamy P Velavan; Olusola Ojurongbe
Journal:  Am J Trop Med Hyg       Date:  2018-01-18       Impact factor: 2.345

3.  Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission.

Authors:  André Lin Ouédraogo; Will Roeffen; Adrian J F Luty; Sake J de Vlas; Issa Nebie; Edith Ilboudo-Sanogo; Nadine Cuzin-Ouattara; Karina Teleen; Alfred B Tiono; Sodiomon Bienvenu Sirima; Jan-Peter Verhave; Teun Bousema; Robert Sauerwein
Journal:  Infect Immun       Date:  2011-10-03       Impact factor: 3.441

4.  Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.

Authors:  Soe Soe; Michael Theisen; Christian Roussilhon; Khin-Saw Aye; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA.

Authors:  Lea Barfod; Nadia L Bernasconi; Madeleine Dahlbäck; David Jarrossay; Pernille Haste Andersen; Ali Salanti; Michael F Ofori; Louise Turner; Mafalda Resende; Morten A Nielsen; Thor G Theander; Federica Sallusto; Antonio Lanzavecchia; Lars Hviid
Journal:  Mol Microbiol       Date:  2006-12-14       Impact factor: 3.501

6.  Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.

Authors:  Issa Nebie; Amidou Diarra; Alphonse Ouedraogo; Issiaka Soulama; Edith C Bougouma; Alfred B Tiono; Amadou T Konate; Roma Chilengi; Michael Theisen; Daniel Dodoo; Ed Remarque; Samuel Bosomprah; Paul Milligan; Sodiomon B Sirima
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

Review 7.  The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.

Authors:  Freya J I Fowkes; Jack S Richards; Julie A Simpson; James G Beeson
Journal:  PLoS Med       Date:  2010-01-19       Impact factor: 11.069

8.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

9.  The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.

Authors:  David Courtin; Mayke Oesterholt; Harm Huismans; Kwadwo Kusi; Jacqueline Milet; Cyril Badaut; Oumar Gaye; Will Roeffen; Edmond J Remarque; Robert Sauerwein; André Garcia; Adrian J F Luty
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

10.  Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.

Authors:  Marco Tamborrini; Markus S Mueller; Sabine A Stoffel; Nicole Westerfeld; Denise Vogel; Francesca Boato; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Malar J       Date:  2009-12-30       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.